HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA ‘Struggles’ Against Spiked Supplements, ‘Thorn’ In Industry’s Side

This article was originally published in The Tan Sheet

Executive Summary

A “continual thorn in the side of responsible” supplement firm is illegally spiked products, industry champion Senator Hatch says. FDA, meanwhile, “struggles to provide effective deterrents” to rid the market of bad actors.

You may also be interested in...



Weight Loss Products Provide Ample Targets In FDA War On Spiked Supplements

FDA finds four weight loss products that contain potentially dangerous undeclared ingredients, including DMAA and sibutramine. The agency also continues to warn about bee pollen with undeclared ingredients.

FDA NDI Draft Is A Push For Tighter Supplement Regulation – Stakeholders

FDA proposed “a pretty crazy” NDI notification draft guidance, says attorney Wes Siegner, because “they think everything is an NDI.” Other stakeholders acknowledge FDA wants tighter regulation of the industry, but say writing and imposing rules for supplement manufacturing is a two-way street.

Another Advertising Review For Goli Nutrition: Church & Dwight Challenges Ashwagandha Claims

NAD review of Goli claims, looking at weight loss, physical performance, sexual function and sales claims, recommended it modify advertising to avoid conveying implied product efficacy claims for Ashwagandha Gummies and modify or discontinue qualified physical performance claim about ingredient KSM-66.

Topics

UsernamePublicRestriction

Register

RS139533

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel